Oral microbiota and host innate immune response in bisphosphonate-related osteonecrosis of the jaw

International Journal of Oral Science

Volumn 6, Issue 4, 2014, Pages 219-226

  Pushalkar, Smruti ^a   Li, Xin ^a   Kurago, Zoya ^a   Ramanathapuram, Lalitha V ^a   Matsumura, Satoko ^a   Fleisher, Kenneth E ^a   Glickman, Robert ^a   Yan, Wenbo ^b   Li, Yihong ^a   Saxena, Deepak ^a  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^b New York She feels blessed to teach our future nurses and advocate for those in need   (United States)

Author keywords

bisphosphonates; denaturing gradient gel electrophoresis; host response; innate immunity; oral microbiota; osteonecrosis of the jaw

Indexed keywords

BONE DENSITY CONSERVATION AGENT; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CATHEPSIN G; CHUK PROTEIN, HUMAN; CTSG PROTEIN, HUMAN; I KAPPA B KINASE; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; MYELOBLASTIN; NOD2 PROTEIN, HUMAN; PEROXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ACTINOBACTERIA; ANTAGONISTS AND INHIBITORS; BACTERIUM; BACTEROIDETES; BIOFILM; CLASSIFICATION; COHORT ANALYSIS; DOWN REGULATION; FEMALE; FUSOBACTERIA; GRAM NEGATIVE BACTERIUM; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; JAW OSTEONECROSIS; MALE; MICROBIOLOGY; MIDDLE AGED; MOUTH; PERIODONTAL DISEASE; PROTEOBACTERIA;

ACTINOBACTERIA; BACTERIA; BACTEROIDETES; BIOFILMS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; CATHEPSIN G; COHORT STUDIES; DOWN-REGULATION; FEMALE; FUSOBACTERIA; GRAM-NEGATIVE BACTERIA; HOST-PATHOGEN INTERACTIONS; HUMANS; I-KAPPA B KINASE; IMMUNITY, INNATE; INTERLEUKIN-6; MALE; MIDDLE AGED; MOUTH; MYELOBLASTIN; NOD2 SIGNALING ADAPTOR PROTEIN; PERIODONTAL DISEASES; PEROXIDASE; PROTEOBACTERIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927560563     PISSN: 16742818     EISSN: 20493169     Source Type: Journal    
DOI: 10.1038/ijos.2014.46     Document Type: Article

References (66)

1. Ruggiero SL, Dodson TB, Assael LA et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009; 67 (5 Suppl): 2-12.
2. Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol 2012; 8 (2): 90-96.
3. Hoefert S, Schmitz I, Tannapfel A et al. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 2010; 14 (3): 271-284.
4. Saia G, Blandamura S, Bettini G et al. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg 2010; 68 (4): 797-804.
5. Ruggiero S, Gralow J, Marx RE et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006; 2 (1): 7-14.
6. Migliorati CA, Schubert MM, Peterson DE et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104 (1): 83-93.
7. Fedele S, Kumar N, Davies R et al. Dental management of patients at risk of osteochemonecrosis of the jaws: a critical review. Oral Dis 2009; 15 (8): 527-537.
8. Diz P, Limeres J, Fedele S et al. Is oral bisphosphonate-related osteonecrosis of the jaw an endemic condition? Med Hypotheses 2012; 78 (2): 315-318.
9. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2, 400 patient cases. J Cancer Res Clin Oncol 2010; 136 (8): 1117-1124.
10. Kos M, Brusco D, Kuebler J et al. Clinical comparison of patients with osteonecrosis of the jaws, with and without a history of bisphosphonates administration. Int J Oral Maxillofac Surg 2010; 39 (11): 1097-1102.
11. Baur DA, Weber JM, Collette DC et al. Osteonecrosis of the jaws unrelated to bisphosphonate exposure: a series of 4 cases. J Oral Maxillofac Surg 2012; 70 (12): 2802-2808.
12. Ikebe T. Pathophysiology of BRONJ: drug-related osteoclastic disease of the jaw. Oral Sci Int 2013; 10 (1): 1-8.
13. Infante-Cossio P, Lopez-Martin JC, Gonzalez-Cardero E et al. Osteonecrosis of the maxilla associated with cancer chemotherapy in patients wearing dentures. J Oral Maxillofac Surg 2012; 70 (7): 1587-1592.
14. Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 2011; 103 (3): 232-240.
15. Sivolella S, Lumachi F, Stellini E et al. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease. Anticancer Res 2013; 33 (5): 1793-1797.
16. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67 (5 Suppl): 61-70.
17. Goda A1, Maruyama F, Michi Y et al. Analysis of the factors affecting the formation of themicrobiome associated with chronic osteomyelitis of the jaw. Clin Microbiol Infect 2014; 20 (5): O309-O317.
18. Hoefert S, Eufinger H. Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 2011; 69 (2): 362-380.
19. Ji X, Pushalkar S, Li Y et al. Antibiotic effects on bacterial profile in osteonecrosis of the jaw. Oral Dis 2012; 18 (1): 85-95.
20. Kumar SK, Gorur A, Schaudinn C et al. The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy. Curr Osteoporos Rep 2010; 8 (1): 40-48.
21. Lesclous P, Abi Najm S, Carrel JP et al. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone 2009; 45 (5): 843-852.
22. Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone 2009; 44 (1): 4-10.
23. Wolf AM, Rumpold H, Tilg H et al. The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica 2006; 91 (9): 1165-1171.
24. Wei X, Pushalkar S, Estilo C et al. Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw. Oral Dis 2012; 18 (6): 602-612.
25. Abu-Id MH, Warnke PH, Gottschalk J et al. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 2008; 36 (2): 95-103.
26. Hansen T, Kunkel M, Weber A et al. Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006; 35 (3): 155-160.
27. Kaplan I, Anavi K, Anavi Y et al. The clinical spectrum of Actinomyces-associated lesions of the oral mucosa and jawbones: correlations with histomorphometric analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108 (5): 738-746.
28. Sedghizadeh PP, Kumar SK, Gorur A et al. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 2008; 66 (4): 767-775.
29. Sedghizadeh PP, Kumar SK, Gorur A et al. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J Am Dent Assoc 2009; 140 (10): 1259-1265.
30. Li Y, Ge Y, Saxena D et al. Genetic profiling of the oral microbiota associated with severe early-childhood caries. J Clin Microbiol 2007; 45 (1): 81-87.
31. Pushalkar S, Ji X, Li Y et al. Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma.BMCMicrobiol 2012; 12: 144.
32. DeSantis TZ, Hugenholtz P, LarsenNet al. Greengenes, a chimera-checked16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 2006; 72 (7): 5069-5072.
33. Dewhirst FE, Chen T, Izard J et al. The human oral microbiome. J Bacteriol 2010; 192 (19): 5002-5017.
34. Roberts AP, Mullany P. Oral biofilms: a reservoir of transferable, bacterial, antimicrobial resistance. Expert Rev Anti Infect Ther 2010; 8 (12): 1441-1450.
35. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358 (9276): 135-138.
36. Sedghizadeh PP, Yooseph S, Fadrosh DWet al.Metagenomic investigation ofmicrobes and viruses in patients with jaw osteonecrosis associated with bisphosphonate therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114 (6): 764-770.
37. Kolenbrander PE, Andersen RN, Blehert DS et al. Communication among oral bacteria. Microbiol Mol Biol Rev 2002; 66 (3): 486-505.
38. Arif N, Sheehy EC, Do T et al. Diversity of Veillonella spp. from sound and carious sites in children. J Dent Res 2008; 87 (3): 278-282.
39. Ota-Tsuzuki C, Alves Mayer MP. Collagenase production and hemolytic activity related to 16S rRNA variability among Parvimonas micra oral isolates. Anaerobe 2010; 16 (1): 38-42.
40. Hsiao WW, Li KL, Liu Z et al. Microbial transformation from normal oral microbiota to acute endodontic infections. BMC Genomics 2012; 13: 345.
41. Gray T. Streptococcus anginosus group: clinical significance of an important group of pathogens. Clin Microbiol Newsl 2005; 27 (20): 155-159.
42. Downes J, Wade WG. Peptostreptococcus stomatis sp. nov., isolated from the human oral cavity. Int J Syst Evol Microbiol 2006; 56 (Pt 4): 751-754.
43. Nakazawa F, Miyakawa H, Fujita M et al. Significance of asaccharolytic Eubacterium and closely related bacterial species in the human oral cavity. J Exp Clin Med 2011; 3 (1): 17-21.
44. Salam MA, SatoM, Hoshino E. Intraperitoneal immune cell responses to Eubacterium saphenum in mice. Microbiol Immunol 2001; 45 (1): 29-37.
45. Gibbons RJ. Bacterial adhesion to oral tissues: a model for infectious diseases. J Dent Res 1989; 68 (5): 750-760.
46. Sedghizadeh PP, Jones AC, LaVallee C et al. Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 115 (2): 224-232.
47. Liu B, Faller LL, Klitgord N et al. Deep sequencing of the oral microbiome reveals signatures of periodontal disease. PLoS One 2012; 7 (6): e37919.
48. Loesche WJ. Bacterial mediators in periodontal disease. Clin Infect Dis 1993; 16 (Suppl 4): S203-S210.
49. Ganguli A, Steward C, Butler SL et al. Bacterial adhesion to bisphosphonate coated hydroxyapatite. J Mater Sci Mater Med 2005; 16 (4): 283-287.
50. Kos M, Luczak K. Bisphosphonates promote jaw osteonecrosis through facilitating bacterial colonisation. Biosci Hypotheses 2009; 2 (1): 34-36.
51. Perrotta I, Cristofaro MG, Amantea M et al. Jaw osteonecrosis in patients treated with bisphosphonates: an ultrastructural study. Ultrastruct Pathol 2010; 34 (4): 207-213.
52. Wanger G, Gorby Y, El-Naggar MY et al. Electrically conductive bacterial nanowires in bisphosphonate-related osteonecrosis of the jaw biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 115 (1): 71-78.
53. Kassolis JD, Scheper M, Jham B et al. Histopathologic findings in bone from edentulous alveolar ridges: a role in osteonecrosis of the jaws? Bone 2010; 47 (1): 127-130.
54. Leibovich SJ, Ross R. The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. Am J Pathol 1975; 78 (1): 71-100.
55. Rappolee DA, Mark D, Banda MJ et al. Wound macrophages express TGF-alpha and other growth factors in vivo: analysis by mRNA phenotyping. Science 1988; 241 (4866): 708-712.
56. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005; 77 (5): 598-625.
57. Raychaudhuri SP, Nguyen CT, Raychaudhuri SK et al. Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimmun Rev 2009; 9 (2): 67-81.
58. Koziol-Montewka M, Magrys A, Paluch-Oles J et al. MPO and cytokines in the serum of cancer patients in the context of Candida colonization and infection. Immunol Invest 2006; 35 (2): 167-179.
59. Lipinski S, Till A, Sina C et al. DUOX2-derived reactive oxygen species are effectors of NOD2-mediated antibacterial responses. J Cell Sci 2009; 122 (Pt 19): 3522-3530.
60. Doumas S, Kolokotronis A, Stefanopoulos P. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun 2005; 73 (3): 1271-1274.
61. Kessenbrock K, Fröhlich L, SixtMet al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest 2008; 118 (7): 2438-2447.
62. Epstein JB, Stevenson-Moore P. Periodontal disease and periodontal management in patients with cancer. Oral Oncol 2001; 37 (8): 613-619.
63. Brunello A, Saia G, Bedogni A et al. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 2009; 44 (1): 173-175.
64. Kamada N, Seo SU, Chen GY et al. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013; 13 (5): 321-335.
65. Favot CL, Forster C, Glogauer M. The effect of bisphosphonate therapy on neutrophil function: a potential biomarker. Int J Oral Maxillofac Surg 2013; 42 (5): 619-626.
66. Henderson B, Nair SP. Hard labour: bacterial infection of the skeleton. Trends Microbiol 2003; 11 (12): 570-577.